The HEBP1 Knockout NCI-H1975 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the NCI-H1975 human lung adenocarcinoma epithelial cell line, engineered to disrupt the HEBP1 gene. This loss-of-function model enables precise investigation of heme binding protein 1 function in a genetically defined non-small cell lung cancer (NSCLC) background. The polyclonal format provides a heterogeneous pool of edited cells, facilitating robust and reproducible functional studies without the clonal variation inherent to single-cell-derived lines.
The NCI-H1975 host cell line is a well-characterized model of NSCLC harboring activating EGFR mutations (L858R and T790M), which confer oncogenic signaling dependency and acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors (TKIs). Derived from a lung adenocarcinoma patient, these epithelial cells are widely employed to dissect mechanisms of EGFR-TKI resistance, including apoptosis evasion and metabolic reprogramming. Their EGFR-mutant background makes them particularly suited for studying therapeutic vulnerabilities and resistance pathways relevant to a substantial subset of lung cancer patients.
HEBP1 encodes a cytoplasmic heme-binding protein that binds heme and interacts with porphyrins, TRAP1, and GAPDH, modulating intracellular heme availability and mitochondrial respiratory chain function. Its expression is regulated by heme levels, oxidative stress, and the transcription factor NRF2. Downstream, HEBP1 governs the release of cytochrome c (CYCS) from mitochondria, a critical step for apoptosome formation and activation of caspase-9 (CASP9) and caspase-3 (CASP3). Additionally, HEBP1 influences the pro-apoptotic BAX and anti-apoptotic BCL2 balance, thereby controlling intrinsic apoptosis. Disruption of HEBP1 is expected to impair heme-dependent cytochrome c mobilization and attenuate caspase cascades, potentially blunting apoptotic responses.
In the context of EGFR-mutant NCI-H1975 cells, HEBP1 knockout provides a powerful tool for exploring the intersection between heme metabolism and drug resistance. EGFR-TKI-resistant NSCLC cells often exhibit mitochondrial dysfunction and altered apoptotic thresholds; by eliminating HEBP1, researchers can determine whether heme dysregulation contributes to the evasion of apoptosis induced by targeted agents such as osimertinib. This model thus facilitates interrogation of HEBP1??s role in maintaining mitochondrial membrane integrity and cytochrome c availability under therapeutic stress, potentially revealing synthetic lethal interactions or heme-targeting strategies to overcome resistance.
This polyclonal knockout product enables investigation of heme metabolism in NSCLC, mitochondrial apoptosis mechanisms, and EGFR-TKI resistance. Key assays include cytochrome c release assays, JC-1 mitochondrial membrane potential measurements, Western blotting for cleaved caspase-3, caspase-9, BAX, and BCL2, and Annexin V/PI apoptosis assays. Further applications encompass RT-qPCR for HMOX1 and ALAS1, co-immunoprecipitation of HEBP1-TRAP1 complexes, flow cytometry for mitochondrial ROS, heme quantification, and osimertinib drug sensitivity testing. For further details, contact Ascent Research.
